Cytosorbents Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Phillip Chan
- Full Time Employees
- 149
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 305 College Road East Princeton NJ United States of America 08540
- IPO Date
- Aug 8, 2006
- CIK
- 0001175151
- Website
- cytosorbents.com
- Similar Companies
- Business
- CytoSorbents Corporation (NASDAQ: CTSO), founded in 1997 and headquartered in Princeton, New Jersey, develops and commercializes blood purification technologies for treating life-threatening conditions in intensive care units, cardiac surgery, and other critical care settings. The company's proprietary platform employs biocompatible, highly porous polymer beads for pore capture and surface adsorption to remove toxic substances, inflammatory cytokines, blood thinners, myoglobin, bilirubin, and other harmful agents from blood and bodily fluids using standard extracorporeal systems such as dialysis machines, CRRT, ECMO, and heart-lung machines. Core products include the flagship CytoSorb, a cytokine adsorber approved in the European Union with CE mark extensions for bilirubin and myoglobin removal in liver disease and trauma, and ticagrelor and rivaroxaban removal in cardiothoracic surgery, distributed in over 70 countries with more than 250,000 devices used to date; CytoSorb 300 for restoring physiological balance in critical care; PuriFi for independent hemoadsorption therapy; ECOS-300CY for ex vivo organ perfusion; VetResQ for veterinary applications available in the U.S.; and products under development such as CytoSorb-XL, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, DrugSorb, and ContrastSorb. CytoSorbents targets sepsis, trauma, burns, ARDS, liver failure, cytokine release syndrome, pancreatitis, rhabdomyolysis, and perioperative bleeding in high-risk cardiothoracic surgery, serving hospitals and clinics globally with a focus on Europe, Asia, and other regions outside the U.S. In recent developments, the company reported third quarter 2025 revenue of $9.5 million, up 10% year-over-year, with gross margins exceeding 70%, and amended its credit agreement with Avenue Capital Group for an additional $2.5 million in cash, extending the interest-only period through December 2026 and providing further flexibility tied to DrugSorb-ATR approval. In September 2024, CytoSorbents submitted a De Novo request to the U.S. FDA for DrugSorb-ATR to reduce perioperative bleeding in CABG patients on ticagrelor, accepted for review in October 2024, though a denial letter issued on April 25, 2025, cited deficiencies now under appeal with a final decision expected in 2025; the company also achieved MDSAP certification and submitted a Medical Device License application to Health Canada in November 2024, anticipating approval in 2025. Additionally, CytoSorbents announced a rights offering in December 2024 to bolster liquidity ahead of potential DrugSorb-ATR launches and pursued strategic growth toward cash flow breakeven in early 2026.
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
CytoSorbents Provides DrugSorb-ATR Regulatory Update
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR